Indinavir

Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].

Product Specifications

CAS Number

[150378-17-9]

Product Name Alternative

MK-639 (free base) ; L-735524 (free base)

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; HIV; HIV Protease; MMP; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/indinavir.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@@H](C[C@H](O)CN(CCN(CC1=CN=CC=C1)C2)[C@@H]2C(NC(C)(C)C)=O)CC3=CC=CC=C3)N[C@H]4C(C=CC=C5)=C5C[C@H]4O

Molecular Formula

C36H47N5O4

Molecular Weight

613.79

Precautions

H315, H319, H320

References & Citations

[1]Chavan S, et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98 (2) :383-9.|[2]Esposito V, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12 (8) :2634-9.|[3]Liu F, et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354 (4) :789-800. |[4]Hall DC Jr, et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646.